scholarly journals The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States

2016 ◽  
Vol 45 (3) ◽  
pp. 455-467 ◽  
Author(s):  
E. H. Elbasha ◽  
M. N. Robertson ◽  
C. Nwankwo
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
The United States ◽  
Genotype 1A ◽  
Treatment Naïve ◽  
The Cost

Estimating the Cost-Effectiveness of OnabotulinumtoxinA for Neurogenic Detrusor Overactivity in the United States

2013 ◽  
Vol 35 (4) ◽  
pp. 414-424 ◽  
Author(s):  
Josh J. Carlson ◽  
Ryan N. Hansen ◽  
Roger R. Dmochowski ◽  
Denise R. Globe ◽  
Danielle C. Colayco ◽  
...  
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Detrusor Overactivity ◽  
The United States ◽  
Neurogenic Detrusor Overactivity ◽  
The Cost

scholarly journals The Cost-Effectiveness of Epilepsy Surgery and Surgical Evaluation in the United States

Neurosurgery ◽  
2019 ◽  
Vol 66 (Supplement_1) ◽  
Author(s):  
Shehryar R Sheikh ◽  
Michael P Steinmetz ◽  
Michael W Kattan ◽  
Mendel Singer ◽  
Belinda Udeh ◽  
...  
Keyword(s):  
United States ◽  
Monte Carlo ◽  
Cost Effectiveness ◽  
Epilepsy Surgery ◽  
Medical Management ◽  
Cost Effective ◽  
The United States ◽  
Effective Strategies ◽  
Surgical Evaluation ◽  
The Cost

Abstract INTRODUCTION Surgery is an effective treatment for many pharmacoresistant temporal lobe epilepsy patients, but incurs considerable cost. It is unknown whether surgery and surgical evaluation are cost-effective strategies in the United States. We aim to evaluate whether 1) surgery is cost-effective for patients who have been deemed surgical candidates when compared to continued medical management, 2) surgical evaluation is cost-effective for patients who have drug-resistant temporal epilepsy and may or may not ultimately be deemed surgical candidates METHODS We use a Monte Carlo simulation method to assess the cost-effectiveness of surgery and surgical evaluation over a lifetime horizon. Patients transition between two health states (‘seizure free’ and ‘having seizures’) as part of a Markov process, based on literature estimates. We adopt both healthcare and societal perspectives, including direct healthcare costs and indirect costs such as lost earnings by patients and care providers. We estimate variability of model predictions using probabilistic and deterministic sensitivity analyses. RESULTS 1) Epilepsy surgery is cost effective in surgically eligible patients by virtue of being cost saving and more effective than medical management in the long run, with 95% of 10 000 Monte Carlo simulations favoring surgery. From a societal perspective, surgery becomes cost effective within 3 yr. At 5 yr, surgery has an incremental cost-effectiveness ratio (ICER) of $31,600, which is significantly below the societal willingness-to-pay (∼ $100,000/quality-adjusted life years (QALY)) and comparable to hip/knee arthroplasty. 2) Surgical evaluation is cost-effective in pharmacoresistant patients even if the probability of being deemed a surgical candidate is low (5%-10%). Even if the probability of surgical eligibility is only 10%, surgical referral has an ICER of $96,000/QALY, which is below societal willingness-to-pay. CONCLUSION Epilepsy surgery and surgical evaluation are both cost-effective strategies in the United States. Pharmacoresistant temporal lobe epilepsy patients should be referred for surgical evaluation without hesitation on cost-effectiveness grounds.

The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States

Addiction ◽  
2001 ◽  
Vol 96 (9) ◽  
pp. 1267-1278 ◽  
Author(s):  
Paul G. Barnett ◽  
Gregory S. Zaric ◽  
Margaret L. Brandeau
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Maintenance Therapy ◽  
The United States ◽  
Opiate Addiction ◽  
The Cost

scholarly journals Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States

2013 ◽  
Vol 16 (3) ◽  
pp. A105
Author(s):  
J.J. Carlson ◽  
R.N. Hansen ◽  
R. Dmochowski ◽  
D. Globe ◽  
D. Colayco ◽  
...  
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Detrusor Overactivity ◽  
The United States ◽  
Neurogenic Detrusor Overactivity ◽  
The Cost

scholarly journals Comparing the cost effectiveness of nature-based and coastal adaptation: A case study from the Gulf Coast of the United States

PLoS ONE ◽  
2018 ◽  
Vol 13 (4) ◽  
pp. e0192132 ◽  
Author(s):  
Borja G. Reguero ◽  
Michael W. Beck ◽  
David N. Bresch ◽  
Juliano Calil ◽  
Imen Meliane
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Gulf Coast ◽  
The United States ◽  
Coastal Adaptation ◽  
The Cost
Sign in / Sign up

Export Citation Format

Share Document